Antithrombin Alfa Withdrawn Phase 4 Trials for Neonates on ECMO Treatment

IndicationsStatusPurposePhase
WithdrawnTreatment4
clinicaltrials.gov IdentifierTitleDrugs
NCT01913444Pharmacokinetic Study of Recombinant AT III in Neonates Undergoing ECMO